Congestive Renal Failure (CRF) Market

Congestive Renal Failure (CRF) Market Analysis

The Congestive Renal Failure Market size is estimated at USD 8.09 billion in 2025, and is expected to reach USD 11.14 billion by 2030, at a CAGR of 6.61% during the forecast period (2025-2030).

The growth trajectory of the congestive renal failure (CRF) market is primarily attributed to the increasing prevalence of chronic kidney disease (CKD), the rising incidence of diabetes and hypertension, and the introduction of technologically advanced medical products.

The global rise in CKD cases serves as a significant driver for the expansion of the CRF market. For example, a report published by Nature Reviews Nephrology in April 2024 indicated that approximately 700 million individuals worldwide were affected by CKD in 2023. This surge is largely driven by demographic factors such as aging populations and the growing prevalence of diabetes and hypertension. In low- and middle-income countries, limited access to healthcare services exacerbates the issue, leading to higher mortality and disability rates associated with kidney diseases. These challenges have heightened the demand for early diagnosis, effective treatment, and comprehensive management of CKD, thereby fueling the growth of the CRF market.

Moreover, the high prevalence of diabetes is expected to further accelerate market growth during the forecast period. For instance, a 2023 report by Health New Zealand estimated that 0.32 million individuals in Aotearoa, New Zealand, were living with diabetes, with an age-standardized prevalence rate of 44.3 per 1,000 people. Similarly, the Indian Council of Medical Research – India Diabetes reported in August 2023 that 101 million individuals in India were diagnosed with diabetes. The interaction between these conditions often creates a compounding effect; for example, uncontrolled hypertension can exacerbate diabetic kidney disease, leading to increased renal congestion.

Conversely, kidney failure caused by diabetes or hypertension can further aggravate these conditions, often necessitating dialysis or kidney transplantation, which in turn drives market growth. Additionally, an article published by the Journal of the American Heart Association in September 2022 emphasized that individuals with heart disease, hypertension, and diabetes are at a higher risk of developing congestive renal failure. The same source highlighted that patients with kidney disease frequently experience increased left ventricular (LV) preload due to arterial stiffness and fluid retention, often worsened by high output shunting through dialysis vascular access.

Furthermore, advancements in the market are anticipated to propel growth. For instance, in January 2023, Glenmark Pharmaceuticals Inc. expanded its product portfolio with the launch of Bumetanide Injection USP, a generic version of Bumex Injection (0.25 mg/mL) manufactured by Validus Pharmaceuticals LLC. Available in both single-dose (1 mg/4 mL) and multi-dose (2.5 mg/10 mL) vials, Bumetanide Injection is indicated for the management of edema (excess fluid retention) associated with conditions such as congestive heart failure, liver disease, and kidney disease. This launch underscores Glenmark's commitment to delivering high-quality, affordable generic medications to patients in need.

In conclusion, the increasing prevalence of CKD, coupled with rising rates of diabetes and hypertension, remains a critical factor driving market growth. However, the high costs associated with treatment are expected to act as a significant barrier to market expansion during the forecast period.

Congestive Renal Failure (CRF) Market Trends

Surgery Segment is Expected to Witness a Significant Growth Over the Forecast Period

The surgery segment within the chronic renal failure market includes procedures such as kidney transplantation and the creation of vascular access for dialysis, both aimed at restoring or supporting renal function and enhancing patient outcomes.

These surgical interventions are primarily employed to address conditions like congestive neuropathy and renal failure. For instance, a study published in March 2023 by Kidney Research and Clinical Practice emphasized that venous congestion often leads to excessive renal tubular sodium reabsorption and volume overload. Consequently, renal replacement therapies, including dialysis or kidney transplantation, become essential to manage diuretic-resistant congestion effectively.

Additionally, the increasing adoption of robotic-assisted technology for renal surgeries is anticipated to drive market growth during the forecast period. For example, in April 2023, UC Davis Health transplant surgeons successfully performed one of the first fully robotic nephrectomies on a living donor in the Sacramento region. Robotic-assisted procedures enable smaller incisions for transplantation, often resulting in faster recovery times with reduced pain and minimal scarring compared to traditional surgical methods.

Robotic-assisted surgeries offer superior precision and dexterity compared to conventional open surgeries. This advanced approach facilitates the accurate and meticulous removal of diseased or congested kidney tissues, leading to improved surgical outcomes and a reduction in post-operative complications. These benefits are expected to contribute significantly to the growth of this segment during the forecast period.

Therefore, the various advantages associated with surgical methods for treating patients with congestive renal failure are projected to drive substantial growth in this segment over the forecast period.

North America is Expected to Hold the Significant Share of the Market Over the Forecast Period

North America is anticipated to hold a substantial share of the market during the forecast period, driven by the high prevalence of kidney failure, hypertension, and diabetes in the region, as well as the presence of key players actively introducing advanced treatments for congestive renal failure.

The significant incidence of chronic kidney disease (CKD) in the region is expected to propel market growth. For example, data published by the CDC in May 2024 revealed that in 2023, approximately 35.5 million adults in the United States, or 1 in 7, were affected by CKD. The same report identified diabetes and hypertension as the leading causes of CKD among adults. Similarly, a February 2023 article by the National Center for Biotechnology Information (NCBI) reported that CKD is a major health concern in Canada, impacting nearly 4 million individuals annually. This high prevalence of CKD is projected to significantly contribute to market expansion during the forecast period.

Additionally, the prevalence of diabetes in the region further supports market growth. According to a February 2024 report by the Centers for Disease Control and Prevention, over 8.4% of the adult population in the United States was diagnosed with diabetes. Likewise, a September 2024 report by Statistique Canada indicated that in 2022, more than 2.57 million Canadians were living with diabetes. The substantial diabetic population is a key factor contributing to the increasing incidence of congestive renal failure, thereby driving market growth.

Moreover, active government initiatives and regulatory approvals for treatments targeting congestive renal failure are expected to further enhance market growth. For instance, in June 2023, the Centers for Medicare & Medicaid Services (CMS) proposed a rule under the Prospective Payment System (PPS) for renal dialysis services. As part of the 2024 End Stage Renal Disease (ESRD) PPS, Medicare is projected to allocate USD 6.4 billion to approximately 7,700 ESRD facilities across the United States for providing renal dialysis services.

In another notable development, Travere Therapeutics, Inc. received accelerated FDA approval in February 2023 for FILSPARI (sparsentan), an innovative treatment for adults with primary IgA nephropathy (IgAN) who are at risk of rapid disease progression, as indicated by a urine protein-to-creatinine ratio (UPCR) of 1.5 g/g or higher. The FDA's approval underscores FILSPARI's proven efficacy in reducing proteinuria, a critical marker of disease severity in IgAN, highlighting its potential to deliver significant benefits to patients managing this complex condition.

In conclusion, the high prevalence of kidney failure and diabetes, coupled with active government involvement and regulatory support, is expected to drive market growth in the region during the forecast period.

Congestive Renal Failure (CRF) Industry Overview

The Congestive Renal Failure (CRF) market is consolidated in nature. Prominent players are participating in new product launches, acquisitions, and collaborations to uphold their position in the market. Moreover, the increasing product approvals are also strengthening the market. Some of the key players in the studied market include Medtronic PLC, B. Braun SE, BD, Baxter International Inc., and Novartis AG, among others.

Congestive Renal Failure (CRF) Market Leaders

Congestive Renal Failure (CRF) Market News

• September 2024: Travere Therapeutics, Inc. received approval from the U.S. FDA for FILSPARI (sparsentan) to slow the decline of kidney function in adults with primary IgA nephropathy (IgAN) who are at risk of disease progression. This follows the drug's initial accelerated approval in February 2023, which was granted based on a surrogate marker of proteinuria.
• March 2024: Akebia Therapeutics, Inc. received United States FDA approval for Vafseo (vadadustat) Tablets for the treatment of anemia associated with chronic kidney disease (CKD) in adult patients undergoing dialysis for a minimum of three months.